UPDATE! Is Someone Pumping Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN)?

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN)

UPDATE: After speaking with an executive at Diffusion Pharmaceuticals Inc., StockNewsUnion.com can confirm that a patent was formally issued to the biotech firm yesterday. HOWEVER, and this is important, the patent award was disclosed this past summer. So the financial impact of the patent issuance had already been “baked” into the share price of DFFN before yesterday’s trading when the patent “news” was revealed by a stock news service.

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) has been hit with massive volumes in mid-day trading sending DFFN shares up over 70%. Volumes began spiking around 11:19 AM EST. Trader chat rooms were abuzz on the stock’s activity in the absence of any news release from Diffusion. Rumors began circulating that a web service that caters to day-traders had published an announcement that Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) had been awarded a patent however no confirmation exists outside of that service. Curiously, many traders in the chat rooms who are claiming to be long shares of DFFN expressed glee at the plight of any short-sellers and speculated that DFFN shares would explode further to the upside once the short-sellers covered their positions. However the “short float” on DFFN shares is only 0.06%. It is also highly curious that a day-trading signal service would acquire knowledge of a patent award prior to the release of the news through the company’s official channels.

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) ended yesterday at $2.74 and opened at that price. DFFN’s price held within a few pennies of $2.74 until 11:19 AM EST when volumes started picking up. Eleven minutes later, 11:30 AM EST, the inter-day high of $4.80 would be reached. From that point forward, DFFN shares began a slide and the stock is currently trading around $3.60 at 1:44 PM EST. Already volumes have reached 20 times their normal daily average.

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) is a nano-cap biotech with a market-cap of less than $30 million. A patent award would be huge for such a small company that has reported no sales since 2013 when it reported a figure of $100,000. EPS losses have been fairly heavy. On a diluted share basis EPS losses in 2011 were -$303.86. EPS losses continued each year since and in 2015 the EPS loss was -$12.80. Dilution has also been a nemesis of DFFN shareholders. In 2008, there were 80,000 shares outstanding. By 2015 there were 1.86 million.

Any readers with information on today’s price action surrounding Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) are urged to leave it in the comment box below.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Marc has a degree in economics and a MSc. in Finance. Over his 20-year career, Marc has worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Author: Marcus Anderson

Marc has a degree in economics and a MSc. in Finance. Marc worked for global investment firms in Europe and the United States as an analyst, fund manager, and consultant.

Leave a Reply

Your email address will not be published. Required fields are marked *